Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second

被引：0
|
作者：
Kim, Jin-Hyo [1 ]
Park, Sung-Soo [1 ]
Yoon, Jae-Ho [1 ]
Lee, Sung-Eun [1 ]
Kim, Hee-Je [1 ]
Min, Chang-Ki [1 ]
机构：
[1] Catholic Univ Korea, Seoul St Marys Hematol Hosp, Coll Med, Dept Hematol, 222 Banpodaero, Seoul 06591, South Korea
来源：
BLOOD RESEARCH | 2022年 / 57卷 / 01期
关键词：
CD38;
D O I：
10.5045/br.2022.2021183
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：76 / 80
页数：5
相关论文
共 50 条
  • [21] DOSE-DEPENDENT EFFICACY OF DARATUMUMAB (DARA) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RR MM)
    Lokhorst, H.
    Laubach, J.
    Nahi, H.
    Plesner, T.
    Gimsing, P.
    Hansson, M.
    Minnema, M.
    Lassen, U.
    Krejcik, J.
    Ahmadi, T.
    Khan, I.
    Uhlar, C.
    Lisby, S.
    Basse, L.
    Brun, N.
    Richardson, P.
    HAEMATOLOGICA, 2014, 99 : 106 - 107
  • [22] Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
    Gasparetto, Cristina
    Lentzsch, Suzanne
    Schiller, Gary J.
    Callander, Natalie Scott
    Tuchman, Sascha
    Bahlis, Nizar J.
    White, Darrell
    Chen, Christine
    Baljevic, Muhamed
    Sutherland, Heather J.
    Kotb, Rami
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Bensinger, William
    Rossi, Adriana C.
    Sheehan, Heidi
    Arazy, Melina
    Kai, Kazuharu
    Lipe, Brea
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma
    Hirohiko Shibayama
    Morio Matsumoto
    Hiroshi Kosugi
    Kazuhiro Shibayama
    Hiroshi Yamazaki
    Shinsuke Iida
    International Journal of Hematology, 2021, 113 : 112 - 121
  • [24] Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
    Shackleton, Louisa
    Fay, James
    Smyth, Elizabeth
    Murphy, Philip
    Glavey, Siobhan
    Quinn, John
    EJHAEM, 2020, 1 (01): : 312 - 314
  • [25] DARATUMUMAB IN MONOTHERAPY AND COMBINATION AS TREATMENT IN RELAPSED / REFRACTORY MULTIPLE MYELOMA: EXPERIENCE OF A THIRD LEVEL HOSPITAL
    Auria Caballero, C.
    Gamarro Calvo, S.
    De Poo Rodriguez, M., V
    Martinez Fernandez, R.
    Sanchez Quinones, B.
    Dourdil Sahun, M., V
    Bonafonte Arruga, E.
    Alcacera Lopez, A.
    Palomera Bernal, L.
    HAEMATOLOGICA, 2018, 103 : 124 - 124
  • [26] Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
    Usmani, Saad Z.
    Nahi, Hareth
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Chari, Ajai
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Hellemans, Peter
    Masterson, Tara
    Clemens, Pamela L.
    Luo, Man
    Liu, Kevin
    San-Miguel, Jesus
    BLOOD, 2019, 134 (08) : 668 - 677
  • [27] Correction to: Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Hannah A. Blair
    Drugs, 2018, 78 : 397 - 397
  • [28] Real-world outcomes of daratumumab monotherapy in relapsed/refractory myeloma
    Maouche, N.
    Leary, H.
    Collings, F.
    Tseu, B.
    Djebbari, F.
    Vallance, G.
    Ramasamy, K.
    Kothari, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 125 - 125
  • [29] The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma
    贾亚静
    China Medical Abstracts(Internal Medicine), 2020, 37 (03) : 189 - 189
  • [30] Results of the Daratumumab Monotherapy Early Access Treatment Protocol (EAP) in Patients from Brazil With Relapsed or Refractory Multiple Myeloma
    Crusoe, Edvan de Queiroz
    Pimenta, Flavia
    Maiolino, Angelo
    Rocha, Vanderson
    de Castro, Nelson Siqueira
    Pei, Huiling
    Trufelli, Damila
    Fernandez, Mariana
    Herriot, Luciana Barreto
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E246 - E247
12345